The therapeutic implications of SOX10 loss extend beyond conventional targeted therapies, as SOX10‐deficient melanoma cells exhibit resistance to oncolytic virus immunotherapy—an approach designed to reverse cancer‐associated immune suppression and stimulate antitumor immune responses.140, 141. The gene discussed is SOX10; the disease is cancer.